PRNewsWire
29 Jul 2026, 17:47 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
A securities fraud class action lawsuit has been filed against ADMA Biologics alleging misrepresentations of financial condition, revenue recognition, and inventory distribution. — Allegations of financial fraud and revenue misstatement are high-severity risks that typically lead to loss of investor trust and significant stock devaluation.
-0.80A Culper Research short-seller report alleged that ADMA engaged in channel stuffing and used an undisclosed related-party distributor, Genesis BioPharma. — Channel stuffing is a serious accounting red flag that suggests artificial inflation of sales and likely future revenue collapses.
-0.70ADMA Biologics' stock experienced a cumulative decline of approximately 45% over three trading days in March 2026 following the short-seller report and a Cantor Fitzgerald downgrade. — The sharp price drop confirms a rapid loss of market confidence and high volatility surrounding the company's valuation.
-0.50Continue reading
6 related stories
Top 3 movers · tap to explore
Which stocks this story touches
The company is facing a securities fraud class action lawsuit and significant stock price declines due to alleged misrepresentations.
The company is named in a securities fraud class action lawsuit filed by Hagens Berman.
The company is mentioned as the subject of an investigation into potential shareholder losses and a class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
8h ago
